Evaluating the Therapeutic Potential of Zanubrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma: Evidence to Date [Corrigendum]
Sawalha Y, Bond DA, Alinari L. Onco Targets Ther. 2020;13:6573—6581.
The authors have advised that there is an error in Table 2 on page 6579. The values “37% (0%)” in the first row for the Ibrutinib column should read “10% (0%)”.
The authors apologize for this error and advise it does not affect the conclusions of the paper.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]